Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Americans are drinking more, which puts them at risk of alcohol-related liver disease, heart disease, cancer and accidents.
The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.
Cancer mortality fell by 29% between 1991 and 2017, largely driven by a decline in lung cancer deaths.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
So found a study of more than 1,500 people treated for hep C, including almost 600 people with compensated advanced chronic liver disease.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Curing hep C slashes risk of death for those with liver cancer history
Smoking cessation, a healthy diet, exercise and weight loss could dramatically reduce new liver cancer cases and liver disease deaths.
Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.
Women with a history of the malignancy also survive longer than men after receiving a liver transplant.
Primary biliary cholangitis (PBC) is a chronic liver disease resulting from the destruction of the bile ducts in the liver.
Sustained response to direct-acting antivirals prolonged survival by a year and a half.
People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.
This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.